Dysplasia detection rates under a surveillance program in a tertiary referral center for inflammatory bowel diseases: Real-world data

被引:1
|
作者
Snir, Yifat [1 ,2 ]
Ollech, Jacob E. [1 ,2 ]
Peleg, Noam [1 ,2 ]
Avni-Biron, Irit [1 ,2 ]
Eran-Banai, Hagar [1 ,2 ]
Broitman, Yelena [1 ,2 ]
Sharar-Fischler, Tali [1 ,2 ]
Goren, Idan [1 ,2 ]
Levi, Zohar [1 ,2 ]
Dotan, Iris [1 ,2 ]
Yanai, Henit [1 ,2 ,3 ]
机构
[1] Rabin Med Ctr, Div Gastroenterol, IBD Ctr, Petah Tiqwa, Israel
[2] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel
[3] Rabin Med Ctr, Div Gastroenterol, 39 Zeev Jabotinsky St, IL-4941492 Petah Tiqwa, Israel
关键词
Dye chromoendoscopy; Dysplasia; Quality measure; Surveillance; HIGH-DEFINITION COLONOSCOPY; ULCERATIVE-COLITIS; COLORECTAL-CANCER; CHROMOENDOSCOPY; NEOPLASIA; MANAGEMENT; ENDOSCOPY; STATEMENT; QUALITY; RISK;
D O I
10.1016/j.dld.2023.10.001
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background and aims: Surveillance colonoscopies are crucial for high-risk patients with inflammatory bowel diseases (IBD) to detect colorectal carcinoma (CRC). However, there is no established quality metric for dysplasia detection rate (DDR) in IBD surveillance. This study assessed the DDR in a dedicated surveillance program at a tertiary referral center for IBD. Methods: Consecutive patients with quiescent colitis were enrolled in a cross-sectional study evaluating DDR. High-definition colonoscopy with dye chromoendoscopy (DCE) was performed by a specialized operator. Advanced dysplasia (AD) was defined as low-grade dysplasia >= 10 mm, high -grade dysplasia, or colorectal cancer. Risk factors for dysplasia detection were analyzed. Results: In total, 119 patients underwent 151 procedures, identifying 206 lesions, of which 40 dysplastic with seven AD . Per-lesion and per -procedure DDR were 19.4 % and 20.5 %, respectively. The perprocedure AD detection rate (ADDR) was 4.6 %. A Kudo pit pattern of II -V had a sensitivity of 92.5 % for dysplasia detection but a false positive rate of 64.8 % ( p < 0.001). Age at diagnosis and at index colonoscopy and past or indefinite dysplasia were associated with per -procedure dysplasia detection. Conclusions: In a real-world setting, a dedicated surveillance program achieved a high DDR. We suggest that optimal DDR in high-risk IBD patients be defined and implemented as a standardized quality measure for surveillance programs. (c) 2023 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:265 / 271
页数:7
相关论文
共 50 条
  • [31] Long-term efficacy and safety of vedolizumab in patients with inflammatory bowel diseases: A real-life experience from a tertiary referral center
    Dragoni, Gabriele
    Bagnoli, Siro
    Le Grazie, Marco
    Campani, Claudia
    Rogai, Francesca
    Manetti, Natalia
    Bensi, Carolina
    Macri, Giuseppe
    Galli, Andrea
    Milla, Monica
    JOURNAL OF DIGESTIVE DISEASES, 2019, 20 (05) : 235 - 242
  • [32] Newer Biological Agents in the Treatment of Severe Asthma: Real-World Results from a Tertiary Referral Center
    Voelker, Dayne
    Almodallal, Yahya
    Scrodin, Megan Dulohery
    Lim, Kaiser
    Keogh, Karina
    Patel, Ashokkumar
    Iyer, Vivek
    LUNG, 2020, 198 (04) : 653 - 659
  • [33] Real-World Outcomes of Vedolizumab Therapy in Ulcerative Colitis and Crohn's Disease at a Tertiary Referral Center
    Hoffmann, Peter
    Krisam, Johannes
    Stremmel, Wolfgang
    Gauss, Annika
    DIGESTIVE DISEASES, 2019, 37 (01) : 33 - 44
  • [34] Newer Biological Agents in the Treatment of Severe Asthma: Real-World Results from a Tertiary Referral Center
    Dayne Voelker
    Yahya Almodallal
    Megan Dulohery Scrodin
    Kaiser Lim
    Karina Keogh
    Ashokkumar Patel
    Vivek Iyer
    Lung, 2020, 198 : 653 - 659
  • [35] Real World Experience of Ustekinumab Therapy in Patients at a US Tertiary Inflammatory Bowel Disease Center
    Cleveland, Noa Krugliak
    Normatov, Inessa
    Buisson, Anthony
    Glick, Laura R.
    Zmeter, Nada
    Pekow, Joel
    Cohen, Russell
    Rubin, David T.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2017, 112 : S376 - S376
  • [36] Real-world assessment of biological treatment of inflammatory bowel disease at an Austrian Referral Centre: the ULTIMATE study
    Groechenig, H. P.
    Walter, E.
    Redl, A.
    Bresztowanszky, M.
    Steidl, K.
    Siebert, F.
    Novacek, G.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S266 - S267
  • [37] Comparative Effectiveness of Ustekinumab Versus Adalimumab in Induction of Clinical Response and Remission in Crohn's Disease: Experience of a Real-World Cohort at a Tertiary Care Inflammatory Bowel Disease Referral Center
    Ahmed, Zunirah
    Venkata, Krishna
    Zhang, Nan
    Malik, Talha A.
    GASTROENTEROLOGY RESEARCH, 2019, 12 (05) : 245 - 251
  • [38] Dysplasia and Colorectal Cancer Surveillance in Ulcerative Colitis Patients in Latin America: Real-World Data
    Parra-Izquierdo, Viviana
    Otero-Regino, William
    Juliao-Banos, Fabian
    Frias-Ordonez, Juan Sebastian
    Ibanez-Pinilla, Edgar
    Gil-Parada, Fabio Leonel
    Marulanda-Fernandez, Hernando
    Otero-Parra, Lina
    Otero-Ramos, Elder
    Puentes-Manosalva, Fabian Eduardo
    Rojas, Gerardo Andres Guzman
    Ernest-Suarez, Kenneth
    Villa-Ovalles, Keyla
    Paredes-Mendez, Juan Eloy
    Jara-Alba, Maria Luisa
    Andrade-Zamora, David
    Ardila-Baez, Manuel Alonso
    Florez-Sarmiento, Cristian
    Veitia, Guillermo
    Sanchez, Abel
    Arango-Molano, Lazaro Antonio
    Fluxa, Fernando
    Queiroz, Natalia Sousa Freitas
    Serrano, Mariastella
    CROHNS & COLITIS 360, 2025, 7 (01)
  • [39] Real-world efficacy and safety of vedolizumab among patients with inflammatory bowel disease: A single tertiary medical center experience in Central Taiwan
    Chiu, Yu-Chiao
    Chen, Chia-Chang
    Ko, Chung-Wang
    Liao, Szu-Chia
    Yeh, Hong-Zen
    Chang, Chung-Hsin
    ADVANCES IN DIGESTIVE MEDICINE, 2021, 8 (01) : 40 - 46
  • [40] JAK INHIBITOR DISCONTINUATION RATES: RETROSPECTIVE REAL-WORLD DATA FROM A TERTIARY CENTRE
    Bland, K.
    Ganguly, S.
    Jubber, A.
    Moorthy, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1421 - 1422